Track topics on Twitter Track topics that are important to you
Rob Hockney talks to Fintan Walton about the ongoing evolution of AstraZeneca's alliance management strategy and capabilities, and the increasingly important role that dedicated alliance management plays in the drug development process for big pharma and small biotech companies alike. Rob emphasises the need for flexibility when developing an alliance management strategy and the importance of dialogue between partnering companies. Together, they examine the different metrics by which to measure alliance success and consider how termination does not have to be the end of a potentially profitable relationship. They also discuss the characteristics of an alliance that enables first-class management to make a value-generating difference. In addition, Rob highlights the essential role that alliance management plays in bridging the gap between companies with big differences in size and culture.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...